Meeting
2021 Genitourinary Cancers Symposium
The contribution of germline DNA damage response mutations on prostate cancer risk and prognosis—A UK Biobank whole-exome analysis.
Authors
Niedzica Camacho
AstraZeneca, Cambridge, United Kingdom
Niedzica Camacho , Athena Matakidou
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Prostate Cancer - Advanced Disease
Track
Prostate Cancer - Advanced
Sub Track
Prevention, Screening, and Hereditary Cancers
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 67)
DOI
10.1200/JCO.2021.39.6_suppl.67
Abstract #
67
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Women with pathogenic variants in moderate penetrance breast cancer genes: How frequently do they meet high penetrance genetic testing criteria?
First Author: Nicole Casasanta
Poster
2023 ASCO Genitourinary Cancers Symposium
Inherited risk for prostate cancer (PCa): Following the natural history of men with high-risk genetics using multiparametric MRI (mpMRI).
First Author: Anna Couvillon
Poster
2023 ASCO Genitourinary Cancers Symposium
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.
First Author: Channing Judith Paller
Poster
2023 ASCO Genitourinary Cancers Symposium
TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients with DDR gene-mutated, metastatic castration-sensitive prostate cancer (mCSPC).
First Author: Neeraj Agarwal